Precision Neuroscience
Develops a brain-computer interface intended to help people with paralysis operate digital devices.
$250MSeries D
ParticipantMC
Mubadala Capital
Activity from announced rounds
Activity in this selectionSeries C+
Mubadala Capital is the investment manager whose official portfolio includes Ollin, Alloy, Juvena and Crusoe.
Recorded funding activity
Ollin develops retinal-disease antibodies. Alloy supplies discovery platforms and services, while Crusoe develops computing infrastructure. The manager remains separate from Mubadala Investment Company; the Precision Neuroscience relation stays in draft.
- Rounds participated in
- 3
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $4.2B 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionCrusoe
AI infrastructure combining GPU cloud services, managed AI tools, large-scale data centers and modular AI factories for model developers and enterprises.
$3.9BSeries F (initial close; anticipated total)
LeadAlloy Therapeutics
Drug discovery platforms and integrated development services for biotechnology and pharmaceutical partners.
$40MSeries E
Role not disclosed